panitumumab + ulixertinib

Panitumumab + ulixertinib is an investigational combination therapy consisting of two targeted agents for cancer treatment. Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting its signaling and thereby blocking downstream pathways involved in tumor cell proliferation and survival. Ulixertinib (BVD-523) is a first-in-class small molecule inhibitor of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which are key components of the RAS/RAF/MEK/ERK signaling cascade frequently activated in cancers with MAPK pathway mutations. The rationale for combining these agents is to achieve dual blockade of EGFR-driven and MAPK-driven oncogenic signaling, particularly in tumors such as metastatic colorectal cancer harboring RAS or other MAPK pathway mutations[6][4][7]. This combination is under clinical investigation for advanced gastrointestinal malignancies.